BUSINESS · AI-ASSISTED SUMMARY

SEC and FDA Strengthen Cooperation with New MOU

WHY IT MATTERS

This MOU will help the SEC and FDA to better protect investors and ensure the safety of pharmaceuticals, ultimately maintaining public trust in the financial and healthcare markets.

What happened

The U. S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have entered into a Memorandum of Understanding (MOU) to enhance their cooperation and ensure market integrity. The agreement aims to facilitate the agencies' respective missions of protecting investors and ensuring the safety and efficacy of pharmaceuticals. The MOU will enable the SEC and FDA to share information and coordinate their efforts to address emerging issues and threats to market integrity. The agreement is designed to be flexible and adaptable to changing circumstances, allowing the agencies to respond effectively to new challenges.

LINKED SOURCES

SEC and FDA Announce MOU to Bolster Cooperation and Ensure Market Integrity

U.S. Securities and Exchange Commission · U.S. government work; source-specific terms apply

AI-assisted summary · THELAST.NEWSPublished August 31, 2026 at 10:15 PMUpdated August 31, 2026 at 10:15 PMRevision 11 linked source

THELAST.NEWS is published by Dmitry Yakushev, Cyprus. Briefs are prepared with the help of AI from linked sources and are not individually reviewed by a human editor unless marked otherwise.